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Abstract
Glial cell line derived neurotrophic factor (GDNF) is a neurotrophic factor that has neuroprotective effects in animal models
of Parkinson’s disease (PD) and has been proposed as a PD therapy. GDNF does not cross the blood brain barrier (BBB), and
requires direct intracerebral delivery to be effective. Trojan horse technology, in which GDNF is coupled to a monoclonal
antibody (mAb) against the human insulin receptor (HIR), has been proposed to allow GDNF BBB transport (ArmaGen
Technologies Inc.). In this study we tested the feasibility of HIRMAb-GDNF to induce neuroprotection in parkinsonian
monkeys, as well as its tolerability and safety. Adult rhesus macaques were assessed throughout the study with a clinical
rating scale, a computerized fine motor skills task and general health evaluations. Following baseline measurements, the
animals received a unilateral intracarotid artery MPTP injection. Seven days later the animals were evaluated, matched
according to disability and blindly assigned to receive twice a week iv. treatments (vehicle, 1 or 5 mg/kg HIRmAb-GDNF) for
a period of three months. HIRmAb-GDNF did not improve parkinsonian motor symptoms and induced a dose-dependent
hypersensitivity reaction. Quantification of dopaminergic striatal optical density and stereological nigral cell counts did not
demonstrate differences between treatment groups. Focal pancreatic acinar to ductular metaplasia (ADM) was noted in four
of seven animals treated with 1 mg/kg HIRmAb-GDNF; two of four with ADM also had focal pancreatic intraepithelial
neoplasia 1B (PanIN-1B) lesions. Minimal to mild, focal to multifocal, nonsuppurative myocarditis was noted in all animals in
the 5 mg/kg treatment group. Our results demonstrate that HIRmAb-GDNF dosing in a monkey model of PD is not an
effective neuroprotective strategy and may present serious health risks that should be considered when planning future use
of the IR antibody as a carrier, or of any systemic treatment of a GDNF-containing molecule.
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Introduction
Glial cell line–derived neurotrophic factor (GDNF) is part of the
transforming growth factor beta (TGFb) superfamily and has a
role in the development and maintenance of mesencephalic
dopaminergic neurons [1]. In animal models of Parkinson’s
disease (PD), GDNF has neuroprotective and restorative proper-
ties [1,2,3] and is proposed as a disease-modifying strategy for PD.
Because GDNF is a protein dimer with a molecular weight of 33 to
45 kDa [4] and lacks a specific carrier protein or transporter at
endothelial cells, it cannot cross the blood–brain barrier (BBB).
Chronic intracerebral delivery can be achieved by direct protein
infusion using cannulae and pumps [2,5] or by in vivo [6,7,8,9] or
ex vivo [10,11] gene therapy methods. These approaches require
invasive neurosurgical procedures, however, which is difficult to
justify for early PD cases that are responsive to standard-of-care
drugs [12,13,14].
New delivery methods for systemic GDNF dosing are being
investigated. One of them is a Trojan horse technology in which
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monoclonal antibody (mAb) against a BBB cellular target that
moves GDNF by transcytosis, allowing BBB transport [15,16].
This technology was successfully tested in rodent models of PD
using a chimeric monoclonal antibody against the mouse
transferrin receptor fusion protein (cTfRmAb-GDNF) [17],
suggesting that delivery of GDNF fusion protein may be a viable
treatment option. For clinical application, the mAb against the
human insulin receptor (HIR) is proposed (ArmaGen Technolo-
gies). HIRmAb is not recognized by the rodent insulin receptor,
and therefore a nonhuman primate model of PD is needed for
preclinical evaluation of HIRmAb-GDNF efficacy. HIRmAb-
GDNF is formed by the fusion of the amino terminus of GDNF to
the carboxyl terminus of the CH3 region of the heavy chain of the
chimeric HIRmAb. The fusion protein is a bifunctional molecule,
which binds with high affinity both to the HIR and to the GDNF
receptor (15). The HIRmAb section of the fusion protein binds the
BBB HIR to mediate transport to the brain, and the GDNF of the
fusion protein binds to GFRalpha1 to mediate GDNF pharma-
cologic action (15). In the present study, we tested the feasibility of
HIRmAb-GDNF to safely confer neuroprotection in a nonhuman
primate model of early PD.
Results
GDNF Fusion Protein did not Induce Behavioral
Improvements
Parkinsonian signs were evaluated before and after treatment
using a clinical rating scale (CRS) (Fig. 1A). At baseline, all animals
presented normal behavior according to their age, scoring 0 on the
CRS. At 7 days after a single intracarotid artery administration of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the mon-
keys showed evidence of onset of a hemiparkinsonian syndrome
that included the presence of slight tremors, slowness of
movement, and gait and balance disturbances. The animals that
presented symptom severity corresponding to a CRS score of $9
points were selected, matched according to disability, and blindly
assigned to a treatment group (n = 7, vehicle; n = 5, 1 mg/kg;
n = 3, 5 mg/kg) (Table 1). The CRS scores (mean6S.E) at
7 days after MPTP administration were 10.2960.42 (vehicle
group), 10.160.33 (1 mg/kg group), and 11.3360.93 (5 mg/kg
group). The monkeys were dosed intravenously twice a week for
11 consecutive weeks. From baseline to 8 weeks, no significant
differences between vehicle and the two HIRmAb-GDNF
treatment groups (P . 0.05, Kruskal-Wallis test) were found. At
9 and 10 weeks, no significant difference was found between
vehicle and the 1 mg/kg group (P . 0.05, Mann-Whitney U test);
one monkey in the 5 mg/kg group was euthanized at 9 weeks
because of adverse reaction to the drug. The final scores at 11
weeks after MPTP administration were 8.7960.43 (vehicle group),
9.660.29 (1 mg/kg group), and 9.7560.25 (5 mg/kg group).
The fine motor skills of the monkeys (Fig. 1B) were evaluated
using a computerized testing device. Before MPTP administration
and after 2 months of training, most monkeys were able to
consistently and quickly complete the task with both hands; the
three exceptions were excluded from the fine motor skills analysis.
The sample sizes were n = 6 (vehicle), n = 4 (1 mg/kg), and
n = 2 (5 mg/kg). As noted above one monkey in the 5 mg/kg
group was euthanized at 9 weeks; because the 5 mg/kg group
sample size was so small, it was excluded from the statistical
analysis of the fine motor skills. Two animals in the vehicle-treated
group recovered some function, especially after the second week of
dosing, which in our experience is uncommon with this model
[6,8,18,19]. At the last fine motor skills test (week 10), average task
time in seconds was, for the right hand, 0.6560.03 (vehicle),
0.7460.08 (1 mg/kg), and 0.4560.00 (5 mg/kg); for the left hand,
it was 15.8066.35 (vehicle), 22.7467.26 (1 mg/kg), and
30.0060.00 (5 mg/kg). No significant difference was found
between vehicle and the 1 mg/kg treatment group (P = 0.162
ANOVA).
A Hypersensitivity Response was Observed After Chronic
HIRmAb-GDNF Treatment
The first monkeys that received the 4th dose of HIRmAb-
GDNF (2
nd week of dosing) developed a severe dose-dependent
type I hypersensitivity reaction. Episodes of skin flushes, eyelid
edema, vomiting, urticaria, and in some cases respiratory distress
were observed during and immediately after the infusions and
required diphenhydramine and epinephrine treatment. Subse-
quently, it was decided to limit the number of monkeys in the
high-dose group to the four animals that already received the
dosing and to prophylactically administer diphenhydramine (1 to
2 mg/kg i.m.) to all animals (including the vehicle-treated group).
Four animals that were excluded from behavioral and anatomical
evaluations because of a score of ,9 points in the CRS received
treatments to assess tolerability (n = 1, vehicle; n = 2, 1 mg/kg;
n = 1, 5 mg/kg). The sample sizes for the tolerability assessment
were n = 8 (vehicle), n = 7 (1 mg/kg), and n = 4 (5 mg/kg).
Overall, 7 of the 11 HIRmAb-GDNF-treated monkeys showed
a hypersensitivity response to the drug. The severity of the reaction
was quantitated using a hypersensitivity response scale (see
Methods section). A significant difference in the score was found
at 2.5 weeks (P = 0.045, Kruskal-Wallis test) and at 3 weeks
(P = 0.09) between vehicle and the 5 mg/kg group and at 5.5
weeks between vehicle and the 1 mg/kg group (P = 0.006,
Mann-Whitney U test) (Fig. 1C). The magnitude of the reaction
decreased over time, suggesting progressive tolerability to
HIRmAb-GDNF and a positive effect of the prophylactic
antihistamine treatment. The exception was monkey rh2134 from
the 5 mg/kg treatment group, that developed severe anaphylactic
reactions necessitating discontinued dosing after dose 5. Serum
ELISA against anti-HIRmAb-GDNF antibodies revealed devel-
opment of circulating antibodies against the drug in all HIRmAb-
GDNF-treated animals (Fig. 1D). Anti-HIRmAb-GDNF antibod-
ies at 4 weeks and hypersensitivity response at 2 to 3 weeks were
significantly correlated (Pearson’s correlation coefficient
R = 0.548, P = 0.034).
No significant differences in food intake, feces output, or weight
were observed between groups (Fig. 2). Blood chemistry, glucose
tolerance test, and urinalysis results were also unaffected by
treatment.
A Similar Loss of Dopaminergic Striatal and Nigral
Markers was Observed Between Treatment Groups
At 3 months after initial treatment, all the monkeys were deeply
anesthetized with pentobarbital (up to 35 mg/kg i.v.) and were
euthanized by transcardiac perfusion with heparinized phosphate
buffer solution. A full necropsy was performed; the brains were
harvested and processed for morphological analysis. Dopaminer-
gic nigrostriatal innervation was assessed with immunostaining for
tyrosine hydroxylase (TH) (Fig. 3) and vesicular monoamine
transporter 2 (VMAT2) (Fig. 4). In all the monkeys, qualitative
observation of both markers revealed a unilateral, extensive loss of
positive fibers in the caudate and putamen nucleus, as well as a loss
of immunoreactive neurons in the substantia nigra.
Optical density of striatal TH and VMAT2 immunoreactivity
confirmed a significant unilateral loss across groups (P = 0.001,
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between treatments (P . 0.05, ANOVA) (Fig. 3G and 4G).
Stereological cell counts of TH-positive and VMAT2-positive
cells in the right side (MPTP-treated) of the substantia nigra
showed significantly fewer such cells, compared with the left
(intact) side (P = 0.001, Wilcoxon signed-rank test). No significant
difference was found between treatment groups for either marker
(P . 0.05, ANOVA) (Fig. 3H and 4H).
GDNF Intracerebral Levels did not Differ Between
Treatment Groups
Immunohistochemistry of coronal brain slices was negative for
GDNF in all monkeys (Fig. 5, A to C). GDNF ELISA (Fig. 6)
showed no significant difference between treatment groups
(P . 0.05, ANOVA) (Fig. 5D) in the frontal cortex
[0.02560.009 ng/mg (vehicle), 0.02260.004 ng/mg (1 mg/kg),
and 0.02160.00 ng/mg (5 mg/kg)] or the putamen
[0.02460.009 ng/mg (vehicle), 0.02060.006 (1 mg/kg), and
0.0160.002 (5 mg/kg)]. GDNF levels in the pancreas of the
1 mg/kg group showed a trend toward higher levels, compared
Figure 1. HIRmAb-GDNF does not induce improve parkinsonian signs and is associated with type I hypersensitivity reaction. (A)
Clinical rating score. (B) Fine motor skills task. (C) Hypersensitivity response over time, by treatment group. (D) Optical density (OD) of HIRmAb-GDNF
antibody levels in serum.
doi:10.1371/journal.pone.0039036.g001
Table 1. Number of animals used per treatment group in the
efficacy and safety experiments.
Experiment Vehicle HIRmAb-GDNF
1 mg/kg 5 mg/kg
Treatment efficacy evaluation
Clinical rating scores 7 5 3
Fine motor skills 6 4 2
Morphological analysis 7 5 3
Safety evaluation
Hypersensitivity response 8 7 4
GDNF and antibody levels 8 7 4
doi:10.1371/journal.pone.0039036.t001
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GDNF levels were below the limit of detection in all animals.
Several HIRmAb-GDNF-treated Monkeys Presented with
Focal Metaplastic and Neoplastic Pancreatic Lesions,
Myocarditis, and Hepatitis
Gross postmortem examinations and blind histologic evalua-
tions of major organs were performed on all animals, including the
four animals that did not reach a sufficient PD score and were
blindly assigned to a treatment group for additional safety
assessment (Table 1). Since no gross abnormalities were noted in
the pancreata, one random section from each pancreatic region
(head, body, and tail) was evaluated histologically. A remarkable
histologic finding was the presence of very focal pancreatic acinar
to ductular metaplasia (ADM) in four of the seven monkeys in the
1 mg/kg treatment group. ADM lesions were noted in pancreatic
sections of the body (n=2), head (n=1) and tail (n=1). The
lesions found in the pancreatic body covered an area of 40.5 mm
2
(approximately 0.360.3 mm) in one case and 8,022 mm
2
(5.663.2 mm) in another. The ADM lesion located in the
pancreatic head had an area of 826.9 mm
2 (1.460.8 mm) while
the one in the tail measured 706.1 mm
2 (1.2 mm61 mm). These
lesions were characterized by focal replacement of a lobule of
exocrine acini by one of mucin-producing ductal epithelium,
surrounded by fibrous stroma. There were lobules of complete
replacement of acini with duct epithelium as well as acini with
both acinar cells and duct cells (Fig. 7). Perhaps more importantly,
intraductal papillary changes ,5 mm in diameter, consistent with
pancreatic intraepithelial neoplasia 1B (PanIN1B) were identified
in two of these four animals. The PanIN1B lesions were present in
the tissue sections where ADM lesions were identified, one in the
pancreatic head and one in the body.
All other histologic alterations in the pancreata, including
periductal lymphocytic inflammation and islet enlargement, were
mild and distributed among animals in all treatment groups. None
of the pancreatic sections in any of the animals had interstitial
abnormalities, acute pancreatitis (neutrophil rich inflammation
with necrosis and/or hemorrhage), or chronic pancreatitis
(inflammation with irregular interstitial fibrosis and irreversible
destruction of the exocrine parenchyma)
28.
Nonsuppurative myocarditis was noted in four of the monkeys
in the 5 mg/kg group and in one of the 1 mg/kg group. All of
these animals had exhibited hypersensitivity responses to HIR-
mAb-GDNF and had lesions varying from very mild focal
perivascular lymphocytic infiltration to moderate multifocal
degenerative and fibrosing lymphoplasmacytic myocarditis char-
acterized by myocardiocyte necrosis, interstitial fibrosis, individual
myocardiocyte hypertrophy and rare eosinophils (Fig. 8).
The animal (rh2134) with the most severe anaphylactic response
(had his dosing interrupted after dose 5) had, in addition to
moderate myocarditis, mild multifocal lymphocytic hepatitis with
individual hepatocyte necrosis (Fig. 9A) and skin lesions in the
lumbar region, consistent with a type I hypersensitivity reaction,
Figure 2. HIRmAb-GDNF treatment did not affect food consumption, feces output, or body weight. (A) Ratio of food consumption
overtime (average per week after treatment/average at baseline) (B) Frequency of abnormal feces. (C) Body weight over time.
doi:10.1371/journal.pone.0039036.g002
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39036Figure 3. Tyrosine Hydroxylase (TH) expression is not affected by HIRmAb-GDNF. (A to F) Coronal images of the TH immunostained
striatum at the level of the anterior commissure (A, C, and E) and of the substantia nigra at the level of the red nucleus (B, D, and F) of monkeys
treated with vehicle (A and B), 1 mg/kg (C and D), or 5 mg/kg (E and F) HIRmAb-GDNF. Scale bar: 2.5 mm (A, C, and E); 1 mm (B, D, and F); 110 mm
(insets b, d, and f). (G) Average TH optical density (OD) in the caudate and putamen nucleus. (H) Stereological cell counts of TH-positive neuron cells
in the substantia nigra (SN).
doi:10.1371/journal.pone.0039036.g003
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39036Figure 4. VMAT2 expression is not affected by HIRmAb-GDNF treatment. (A to F) Coronal images of the striatum at the level of the anterior
commissure (A, C, and E) and of the substantia nigra at the level of the red nucleus (B, D, and F) stained with the dopaminergic marker VMAT2 of
monkeys treated with vehicle (A and B), 1 mg/kg (C and D), or 5 mg/kg (E and F) HIRmAb-GDNF. Scale bar: 2.5 mm (A, C, and E); 1 mm (B, D, and F);
110 mm (insets b, d, and f). (G) VMAT2 optical density (OD) in the caudate and putamen nucleus. (H) Stereological cell counts of VMAT2-positive
neuron cells in the substantia nigra.
doi:10.1371/journal.pone.0039036.g004
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cular lymphocytic dermatitis (Fig. 9, B and C). These lesions were
observed at necropsy 7 weeks after cessation of HIRmAb-GDNF
dosing. An additional animal (r02104) in the 1 mg/kg group had
mild multifocal lymphocytic necrotizing hepatitis.
Discussion
Our results demonstrate that administration of HIRmAb-
GDNF biweekly for a period of 3 months to MPTP-treated
monkeys does not confer behavioral or anatomical neuropro-
Figure 5. GDNF was not intracerebrally detected by immunohistochemistry or ELISA methods. (A to C) Coronal images of GDNF
immunostained striatal sections of vehicle (A), 1 mg/kg (B), and 5 mg/kg (C) HIRmAb-GDNF treatments. *Inset in (A) corresponds to a positive control
tissue stained in parallel from a monkey that received intracerebral injections of human neuroprogenitor cells expressing GDNF. Scale bar: 1 mm. (D
and E) ELISA determination of GDNF levels in the brain (D) and in the pancreas (E).
doi:10.1371/journal.pone.0039036.g005
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response, associated with the development of antibodies against
HIRmAb-GDNF, was observed starting during the fourth dose
of HIRmAb-GDNF in all four animals in the 5 mg/kg
treatment group and in four of the seven animals in the
1 mg/kg group. Focal pancreatic ADM, PanINs, myocarditis,
and hepatitis were identified histologically in HIRmAb-GDNF-
treated monkeys.
Figure 6. ELISA GDNF and HIRmAb-GDNF standard curves, optical density (OD) versus concentration.
doi:10.1371/journal.pone.0039036.g006
Figure 7. GDNF fusion protein dosing was associated with pancreatic lesions in low dose treatment groups. (A and B)
Microphotographs of H&E-stained pancreas from monkeys treated with vehicle [r02048 (A) normal pancreas] or 1 mg/kg HIRmAb-GDNF [r99022 (B)
pancreas with ADM]. Scale bar: 125 mm. (C normal pancreas and D pancreas with ADM) Higher-magnification views correspond to the boxed areas in
(A) and (B). Scale bar: 25 mm. In the HIRmAb-GDNF-treated animal (B), note the extensive acinar to ductular metaplasia (green outline) surrounding
large pancreatic ducts (*) and extending irregularly into the exocrine parenchyma; the corresponding higher-magnification image (D) shows the
junction between normal pancreas (right) and acinar to ductular metaplasia (left), with a lobule of acinar cells replaced by cells with ductal
differentiation (a) surrounded by fibrous stroma (b) and an exocrine acinus with both acinar and ductal cell morphology (arrow).
doi:10.1371/journal.pone.0039036.g007
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antiparkinsonian effects in several animal models of PD, including
MPTP-treated monkeys [1,2,3]. Studies in rodent models with
cTfRmAb-GDNF, a compound analogous to HIRmAb-GDNF,
have also shown neuroprotective properties [17]. Moreover,
HIRmAb-GDNF activity has been previously documented in cell
culture assays and in a rat model of stroke, using direct
intracerebral injection [15]. Nonetheless, no neuroprotective or
antiparkinsonian effects were detected in the present study in
monkeys. It should be noted that two animals in the vehicle-
treated group recovered some function in the fine motor skills task,
a finding that in our experience is unusual [18,19,20]. Morpho-
logical analysis confirmed that these two monkeys had significant
dopaminergic lesions, comparable to those of other subjects. The
partial functional improvement may have been facilitated by
diphenhydramine hydrochloride dosing, because this drug has
known antiparkinsonian properties related to its central anticho-
linergic activity (21,22,23).
Several possible explanations can be proposed for the lack of
efficacy of HIRmAb-GDNF, including limitations of the testing
paradigm, low dose of HIRmAb-GDNF, GDNF inactivation by
immune reaction, or low BBB penetration of GDNF due to
antibody blocking to the HIR and/or transcytosis.
The experimental design used for the present study replicates a
previously validated paradigm for GDNF efficacy [6,8]. Using this
paradigm, our research group has previously shown that delivery
of GDNF by in vivo gene therapy methods, starting 1 week after
MPTP challenge, can prevent the functional and neuroanatomical
effects of MPTP in young monkeys [6] and in aged monkeys [8].
In this paradigm, clinical effect is associated with at least 2 ng/mg
(total protein) of GDNF in the putamen nucleus [6,8]. These
reports suggest that the present experimental design was appro-
priate and that, if effective dosing of GDNF is achieved, the
treatment should be efficacious.
The dosing and the method of administration of HIRmAb-
GDNF were based on previous biosafety and pharmacokinetics
monkey studies that showed effective BBB penetrance without
adverse effects. Administration of 0.2 mg/kg of [
125I]-HIRmAb-
GDNF led to a 10-fold increase in GDNF concentration in the
brain, compared with administration of [
125I]-GDNF [21,22]. At
47 hours after administration of 10 mg/kg HIRmAb-GDNF, the
GDNF concentration in cerebrospinal fluid ranged from 1.2 to
3.6 ng/mL; after a dosing of 0.4 or 2 mg/kg, it was below the limit
of detection (1 ng/mL) [21,22]. In the present study, the lack of
detection of GDNF 24 hours after 1 mg/kg dosing could be
explained if the drug was already metabolized and the levels were
beyond the sensitivity of the method.
A difference between the present study and previous reports is
that the brains and all organs were collected after saline perfusion,
which would decrease the risk of drug retention within the
Figure 8. GDNF fusion protein dosing was associated with myocarditis. (A to D) Microphotographs of the heart of monkeys treated with
vehicle (A and C) or 5 mg/kg HIRmAb-GDNF (B and D) (H&E staining). The HIRmAb-GDNF-treated animal [rh2134 (B)] shows a moderate multifocal
degeneration with interstitial fibrosis (*) and individual myocardiocyte hypertrophy (arrow). Higher-magnification images in (C) and (D) correspond to
boxed areas in (A) and (B). Note the presence of lymphocytes, plasma cells, and rare eosinophils in (D). Scale bar: 100 mm (A and B); 25 mm (C and D).
doi:10.1371/journal.pone.0039036.g008
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tissue samples. This collection method may have also affected
pancreatic GDNF levels; we found only a trend toward higher
levels in HIRmAb-GDNF-treated animals, compared with vehicle
treatment. A higher dose, such as the reported 10 mg/kg (25),
might induce higher intracerebral levels of GDNF, and thus
provide greater neuroprotection; however, the severity of the
immune reaction in macaques to HIRmAb-GDNF at the 5 mg/kg
dose precludes attempting that strategy (unless with concurrent
aggressive immunomodulating therapy to prevent the develop-
ment of type I hypersensitivities, especially anaphylactic reactions).
Evaluation of potential antibody formation and toxicity is
accepted standard practice during preclinical testing of biologi-
cally-derived therapies, like HIRmAb-GDNF, as the chronic
administration of these treatments are associated with the
development of antidrug antibodies that may affect the efficacy
and toxicological profile of the test article (26–28). The immuno-
logical reaction against HIRmAb-GDNF may have affected its
neuroprotective properties in several possible ways. The antibodies
may have bound to HIRmAb-GDNF, neutralizing the drug and/
or facilitating its metabolism. If the antibodies inhibited HIRmAb
capacity to bind to its BBB target, the drug would not have
reached the nigrostriatal system, decreasing its efficacy. It should
also be mentioned that while some of the observed adverse effects
may have been facilitated by the immune response (see below),
others may have been underestimated due to changes in
pharmacokinetics.
Necropsy and histology revealed the presence of acute to
subacute nonsuppurative myocarditis in the four animals that
received 5 mg/kg treatment and in one animal that received
1 mg/kg treatment. Severe allergic or anaphylactic reactions can
induce myocarditis [23], which may explain the finding in the
present study. Although GDNF cardiac adverse effects have not
been previously reported, systemic delivery of HIRmAb-GDNF
induces levels in the heart 30 times higher than does GDNF [21],
thereby increasing the potential of adverse effects. Whereas the
GDNF receptor Ret is located on cardiac ganglion neurons [24],
the insulin receptor (IR) is present on vascular endothelial cells and
cardiac myocytes [25]. Given that muscle inflammation and high
carbohydrate requirements are associated [26], it is possible that a
high dose of a fusion protein that links to the insulin receptor may
also be involved in the onset of myocarditis.
Pancreatic metaplasia and neoplasia appear to be rare in rhesus
macaques, and neoplastic lesions are especially uncommon in
macaques under 10 years of age [27]. A retrospective search of 30
years of biopsy and necropsy records (2,540 animals) at the
Wisconsin National Primate Research Center (WNPRC) yielded
no diagnoses of pancreatic acinar to ductular metaplasia (ADM) or
pancreatic intraepithelial neoplasia 1B (PanIN1B). ADM is
characterized by abnormal transformation of mature acinar cells
to cells with ductal differentiation [28], similar to our histologic
findings in the four monkeys treated with 1 mg/kg HIRmAb-
GDNF. Although ADM can be secondary to duct obstruction and
other mechanical processes, ADM has also been linked to
pancreatic neoplasia. ADM and lobulocentric atrophy are
frequently observed in association with PanIN lesions, and ADM
is a prominent component of many genetically engineered mouse
models of pancreatic cancer, where such lesions often precede the
appearance of PanINs [29,30,31].
In contrast to ADM, PanIN lesions in humans are currently
regarded as neoplasms that can be precursors to invasive
pancreatic cancer [32]. The PanIN classification system, which
was created to facilitate consistent diagnosis, is built upon clinical
and morphological observations, as well as molecular genetic
Figure 9. GDNF fusion protein dosing induced response lesions
in the liver and the skin, associated with anaphylactic
responses. (A to C) Microphotographs of the liver (A) and the skin
(B and C) of a monkey (rh2134) treated with 5 mg/kg HIRmAb-GDNF
(H&E staining). Scale bar: 100 mm (A and B); 50 mm (C). (A) Liver shows
mild multifocal lymphocytic hepatitis with necrosis of individual
hepatocytes. (B) Dermis shows subdermal hemorrhage (a) saponifica-
tion of tissue adipocytes, and mild lymphocytic dermatitis. (b). (C)
Dermis shows mild lymphocytic perivascular and periadnexal derma-
titis.
doi:10.1371/journal.pone.0039036.g009
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increasingly atypical morphology as well as the increasing
prevalence of mutational events with the highest grade PanINs
most closely resembling pancreatic cancer (invasive ductal
adenocarcinoma) [33,34]. Although there is a striking morpho-
logic resemblance between the lesions in this report and PanINs in
mice and humans, further studies are necessary to determine
whether the pancreatic lesions observed in macaques contain the
same clonal genetic mutations or other more definitive markers of
true neoplasms, as noted in human pancreata with PanINs and
invasive adenocarcinoma. Such genetic evidence would strengthen
the morphologic impression that the pancreata of these macaques
contain focal neoplastic premalignant lesions.
The occurrence of metaplastic and neoplastic pancreatic lesions
in young adult rhesus monkeys chronically exposed to HIRmAb-
GDNF suggests a drug-related effect. There are no previous
reports of pancreatic toxicity of GDNF, but most safety studies
administered GDNF intracerebrally [35] or for a shorter period of
time [22]. GDNF has been reported to promote tumor cell
invasion in pancreatic cancer cell lines [36], and GDNF is strongly
expressed in intrapancreatic nerves [37]. High levels of the GDNF
receptor RET have been observed in pancreatic cancer cells, and
genetic variation in RET has been linked to variation in
proliferation and invasion in pancreatic cancer cells; because its
levels of expression have a negative correlation with survival rate,
RET has been proposed as a prognostic marker [37,38].
Moreover, GDNF induces perineural invasion in pancreatic
cancers, and inhibition of RET signaling suppressed perineural
invasion [39]. These studies provide evidence of the role of GDNF
signaling in pancreatic neoplasia but at a far later stage in the
neoplastic process than the changes observed in the current study.
The coupling of GDNF to HIRmAb may have facilitated the
accumulation of the compound in the pancreas, because numerous
insulin receptors are present in the duct cells [40,41]. This may
have also contributed to overactivation of tyrosine kinase signaling
pathways that are stimulated by both GDNF and insulin, affecting
duct cells normal metabolic function. It can be argued that the
lesions in the monkeys were facilitated by their exposure to MPTP,
a dopaminergic toxin that inhibits mitochondrial complex I [42],
but several lines of evidence argue against this. Although chronic
exposure to toxins has been suggested as a risk factor for
pancreatic cancer (e.g.: smoking), the animals in the present study
were treated with a single, not chronic, central injection of MPTP,
which limited peripheral effects of the neurotoxin. Furthermore,
HIRmAb-GDNF dosing was started after MPTP clearance
[1 week after intoxication [43]], which minimized any potential
interaction between compounds and allowed the animals to
recover from the surgical procedure. None of the animals were
noted to have clinical symptoms of acute or chronic pancreatitis.
Complete necropsies with histology are performed on every
animal that dies or is euthanized at the WNPRC, and in our
extensive experience with MPTP-treated monkeys, we have not
observed gross or histologic pancreatic lesions. To our knowledge,
there are no reports of pancreatic lesions in MPTP-treated
monkeys. Additionally, none of the vehicle-treated monkeys had
ADM or PanINs.
In summary, chronic administration of HIRmAb-GDNF failed
to show behavioral and anatomical efficacy and was associated
with severe adverse effects that preclude further studies toward
clinical translation for PD or other chronic conditions. An increase
in the dose of HIRmAb-GDNF or coadministration of immuno-
modulating therapy may increase its efficacy, but the potential for
an adverse response in nonhuman primates is considerable, in
light of the severity of the type I hypersensitivity (anaphylactic)
reactions and the finding of pancreatic metaplasia and PanINs
after a relatively short dosing period. The specific role of the HIR
antibody or of GDNF in producing the immune reactions, or more
importantly the pancreatic changes, are unclear from this limited
dataset. It is possible that either or both responses require a
bivalent ligand. In any event, the potential for these lesions would
need to be considered in any future use of the IR antibody as a
carrier, or of any systemic treatment of a GDNF-containing
molecule. Although at this time additional toxicological studies are
needed, it may be possible that short exposure to this compound
for other indications (e.g. stroke) is safe.
Our findings highlight the importance of comprehensive
preclinical research in nonhuman primates to assess first-in-class
therapies. While this study cannot predict whether HIR-mAb
GDNF will also induce an immune response in humans,
accumulated evidence using biologically-derived therapies advises
caution.
Materials and Methods
Ethics Statement
The present study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health (1996)
in an AAALAC accredited facility (Wisconsin National Primate
Research Center, University of Wisconsin - Madison). The
experimental protocol was approved by the Institutional Animal
Care and Use Committee at the University of Wisconsin -Madison
(permit no. G00564). All efforts were made to minimize the
number of animals used and to ameliorate any distress.
Subjects
Adult male rhesus monkeys (Macaca mulatta; 5–11 years old, 6–
12 kg) were used in the present study; for animal numbers in
different experiments, see Table 1. Animals were housed
individually on a 12-hour light/dark cycle and received food
and water ad libitum. The animals’ diet was supplemented with
fruit during testing sessions. General monitoring during the study
included weight, food intake, feces output and condition, blood
pressure, blood chemistry, intravenous glucose tolerance test, and
urinalysis.
Behavioral Evaluations
Animals were trained and blindly evaluated using positive
reinforcement. Parkinsonian symptoms (tremor, posture, gait,
bradykinesia, balance, upper motor skill, and defense reaction)
were assessed throughout the study with a previously validated
clinical rating scale (CRS) as described [44,45]. The scale ranges
from 0 to 32, with a score of 0 corresponding to normal behavior
and 32 to extreme severe parkinsonian symptoms. Observation
began two weeks before any experimental intervention to establish
a baseline rating score.
Fine motor skills were tested 3 days per week using a monkey
movement analysis panel (mMAP) in a food retrieval task as
described [45]. Each test consisted of twelve total trials alternating
between arms, six per side. Delaying feeding time until after the
task was completed ensured animals’ compliance with the test.
Data collected included the time taken for the animal to move its
hand into the chamber where the fruit was located (reaction time),
the time taken to pick up the fruit while the hand was in the
chamber (reception time) and the total time taken to move the
hand into the chamber, retrieve the fruit and bring the hand back
out of the panel and into the cage (total time). The animals were
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took place.
Induction of Parkinsonian Syndrome
Two months after behavioral training, 22 rhesus monkeys
received a single intracarotid infusion of 3 to 4 mg of MPTP-HCl
(Sigma-Aldrich, lot no. 128K1549) in 20 mL saline solution
delivered at a rate of 1.33 mL/min under sterile surgical
conditions as described [18]. At 1 week after MPTP administra-
tion, animals were evaluated with the CRS. The 15 animals that
scored $9 points were selected, matched according to disability,
and blindly assigned to one of three treatment groups (see Table 1).
Three animals were excluded from the present study because of
death after MPTP administration. Four animals were excluded
from the efficacy evaluations because of clinical score of ,9 points,
but these animals received treatments and were included in the
tolerability studies.
HIRmAb-GDNF Treatment
At 1 week after MPTP administration, the monkeys began
receiving intravenous infusions of HIRmAb-GDNF (1.0 or
5.0 mg/kg) or vehicle (acetate buffered saline) twice a week, in
the morning before feeding, for a total of 22 doses over an 11-week
treatment period. HIRmAb-GDNF (AGT-190) was provided by
ArmaGen Technologies. The compound was manufactured in a
bioreactor as described [15,22]. The study drug was diluted in
50 mL of normal saline (Baxter Laboratories) and was adminis-
tered by intravenous infusion at a rate of 3.0 to 3.5 mL/min. The
animals were sedated with ketamine (up to 10 mg/kg i.m.) for the
infusion period and were closely monitored by veterinarians.
Hypersensitivity Response Scale
The animals’ response to HIRmAb-GDNF or vehicle treat-
ments was scored using a hypersensitivity response scale. The scale
consists of five points of increasing severity of symptoms observed
after dosing: 0, no clinical remarks; 1, slow recovery from drug
injection; 2, skin flushes (mainly on face); 3, skin abnormalities (red
bumps, white dots) and/or edema and/or vomit; 4, respiratory
abnormalities (tachypnea) and skin abnormalities and/or edema
and/or vomit; and 5, respiratory abnormalities and hypotension
and tonic-clonic movement of limbs and skin abnormalities and/
or edema and/or vomit.
Necropsy and Preparation of Tissue
At 12 weeks after MPTP administration and 24 hours after the
final treatment dose, the monkeys were necropsied, with the
exception of one subject (rh2134; 5.0 mg/kg group), which
received no further treatment doses after 9 weeks because of
health concerns. The animals were euthanized by transcardiac
perfusion with heparinized phosphate buffer solution (PBS) under
pentobarbital anesthesia (up to 35 mg/kg i.v.). Before death, blood
and cerebrospinal fluid samples were obtained to evaluate GDNF
levels, and serum was sampled to check for the presence of GDNF
antibodies. The brains were harvested and sectioned using an
acrylic glass calibrated apparatus; tissue punches of the putamen
and cortex were obtained, quickly frozen and kept at 280C until
biochemical analysis. The rest of the brain tissue was post-fixed in
4% paraformaldehyde for 72 hours and cryoprotected by immer-
sion in a graded (10% to 30%) sucrose/PBS solution. The tissue
slabs were cut frozen (40-mm sections) on a sliding knife
microtome. All sections were stored in a cryoprotectant solution
before processing [46]. Coronal brain sections were used for
immunohistochemical staining according to our previously pub-
lished protocols [47]. The antibodies used were against tyrosine
hydroxylase (TH; 1:20,000; ImmunoStar), vesicular amine trans-
porter 2 (VMAT2; 1:1,000; Phoenix Pharmaceuticals), and GDNF
(1:250; R&D Systems).
Pancreata were dissected in their entirety, weighed, sectioned
into three regions (head, body, and tail) and each region bisected
for either biochemical or histological evaluation. For biochemical
analysis the tissue was quickly frozen and kept at 280C until
processing. For histology, the samples were fixed in 10% neutral
buffered formalin (10% NBF), routinely processed, embedded in
paraffin, sectioned into 5 mm slices, and stained with hematoxylin
and eosin.
Other body tissues collected were pituitary gland, spinal cord,
injection sites, stomach, duodenum, jejunum, ileum, cecum, colon,
rectum, liver, gallbladder, lung, kidneys, thyroid glands, trachea,
esophagus, ascending aorta, adrenal glands, axillary lymph nodes,
inguinal lymph nodes, mesenteric lymph nodes, mandibular
salivary glands, spleen, tongue, skeletal muscle, urinary bladder,
diaphragm, testes, epididymides, seminal vesicles, prostate gland,
prostatic urethra, eyes (entire globe, including optic nerve), bone,
bone marrow, thymus, and heart, as well as any lesions noted
during gross examination. Tissues were fixed, processed and
sectioned as for pancreata. All tissues were histologically evaluated
by a veterinary pathologist (HAS) blind to the treatment condition.
Neuroanatomical Evaluations
The optical density (OD) of TH or VMAT2-immunoreactive
(ir) fibers was blindly quantified within ventral, medial, and dorsal
sections of both the caudate and the putamen using NIH ImageJ
software version 1.44 described [8]. The total number of TH-ir
and VMAT2-ir neurons in the right and left as substantia nigra
(SN) was blindly calculated using unbiased stereological cell-
counting methods, as described [44,48,49,50].
Pancreatic Evaluations
A representative section from the head, body, and tail of each
pancreas were first blindly evaluated by a veterinary pathologist
(HAS). This initial analysis was followed by blind evaluations of
the sections by two M.D. pathologists, experts in pancreatic
pathology (LDW & RHH). Pancreatic sections were evaluated for
histologic changes such as inflammation, atrophy, dysplasia,
neoplasia, and deposition of substances such as amyloid. Changes
in the exocrine acini, islets, ducts, and pancreatic interstitium were
described and charted for comparison among animals. The ADM
lesions were measured using SPOT advanced 4.6 software in an
Olympus BX41 microscope, coupled with a SPOT Insight 2MP
color Mosaic digital camera.
GDNF and HIRmAb-GDNF Antibody ELISA
GDNF levels in frontal cortex, right medial putamen, pancreas,
and sera taken from monkeys at necropsy were analyzed by
ELISA (R&D Systems), according to the manufacturer’s guidelines
and as described [8].
HIRmAb-GDNF antibody levels were evaluated in sera using
ELISA as described [22], with minor changes. A microtiter plate
was precoated with HIRmAb-GDNF (250 ng/well) overnight at
4uC and was blocked with a blocking buffer (R&D Systems). The
plate was incubated for 1 hour at room temperature with the sera
(1:1000 dilution) from monkeys withdrawn during the 12-week
treatment study, followed by a 1:500,000 dilution of biotinylated
goat anti-monkey IgG (LifeSpan BioScience) for 1 hour and
streptavidin-horseradish peroxidase (R&D Systems). Color was
visualized using a peroxidase substrate system (R&D Systems).
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reference at 570 nm.
Statistical Analysis
All data were collected and analyzed by investigators blind to
the treatment groups. Statistical significance was set at P,0.05. All
statistical analyses were performed using PASW Statistics 18.0
software (SPSS).
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